The 21st Century Cures Act, also known as the Cures Act, provides the National Institutes of Health (NIH) with critical tools and resources to advance biomedical research across the spectrum, from foundational basic research studies to advanced clinical trials of promising new therapies. Both the U.S. House of Representatives and the Senate passed it with strong bipartisan support, and it became law on December 13, 2016.
Explore this issue:August 2017
The legislation provides $4.8 billion in funding to four highly innovative scientific initiatives over the next 10 years, including the All of Us Research Program, formerly known as the PMI Cohort Program ($1.45 billion), the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative ($1.5 billion), Cancer Moonshot ($1.8 billion), and the Regenerative Medicine Innovation Project ($30 million) (See Table 1).
“Funding to the NIH has been one of the most critical drivers of improved health in the world,” said Joseph E. Kerschner, MD, professor of otolaryngology, microbiology, and immunology, dean of the School of Medicine, and executive vice president of the Medical College of Wisconsin in Milwaukee. “Virtually every disorder that an otolaryngologist comes into contact with has been altered, with improved patient outcomes, because of NIH-funded research. Specifically, the Cures Act includes increased funding to the NIH for cancer research—including cancer of the head and neck—which has the tremendous potential to make significant progress toward improved care and survival rates. Other areas of emphasis include funding for research in opioid use, behavioral health, and access to healthcare, which are critical areas impacting otolaryngologists and their patients.”